Atorvastatin Inhibited ROS Generation and Increased IL-1β And IL-6 Release by Mononuclear Cells from Diabetic...

Area of Science:

• Immunology
• Metabolic Research
• Pharmacology

Background:

• Atorvastatin (ATV) is known for lowering LDL cholesterol by inhibiting HMG-CoA reductase.
• Beyond cholesterol reduction, ATV exhibits diverse metabolic effects.
• Understanding these pleiotropic actions is crucial for comprehensive patient care.

Purpose of the Study:

• To investigate the impact of Atorvastatin on reactive oxygen species (ROS) generation.
• To assess Atorvastatin's effect on cytokine secretion (IL-1β and IL-6) in immune cells.
• To compare these effects in Type 2 Diabetes Mellitus (T2DM) patients versus healthy individuals.

Main Methods:

• Assessed NADPH-oxidase and mitochondrial ROS generation using chemiluminescence and Dichlorofluorescein Assay (DCFH-DA).
• Quantified IL-1β and IL-6 levels via Enzyme-Linked Immunosorbent Assay (ELISA).
• Evaluated effects in Peripheral Blood Mononuclear Cells (PBMNC) from T2DM patients and controls.

Main Results:

• ATV inhibited NADPH-oxidase dependent ROS generation but not mitochondrial ROS.
• ATV activated IL-1β and IL-6 secretion in PBMNC from both T2DM patients and controls.
• These effects were comparable to those observed with a Protein Kinase Cβ inhibitor (iPKCβ).
• ATV potentiated lipopolysaccharide (LPS)-induced IL-1β and IL-6 secretion.

Conclusions:

• Atorvastatin inhibits ROS generation and activates IL-1β/IL-6 secretion in PBMNC of diabetes patients.
• The observed effects of ATV on ROS and cytokine secretion were independent of hyperglycemia.
• These findings highlight non-lipid-lowering effects of Atorvastatin on immune cell function.